What the Latest Research Says About Ozempic and Gastroparesis

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health to Occupational Vigilance

If you've been taking Ozempic and are concerned about persistent nausea, vomiting, or abdominal pain, you may be wondering about the risk of gastroparesis. Medical literature has long recognized that certain medications can affect gastric motility, and recent studies have focused on GLP-1 receptor agonists like Ozempic. This page provides an objective overview of current research updates, FDA warnings, and what patients should know.

Bridging to Ozempic and Gastroparesis

Building on the need for targeted monitoring, we now examine a specific pharmaceutical agent—Ozempic (semaglutide)—and its potential link to gastroparesis, a condition characterized by delayed gastric emptying without mechanical obstruction. Ozempic is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes and for chronic weight management. Among its known adverse effects, gastrointestinal reactions are prominent and have raised concerns about a potential causal relationship with gastroparesis. This section explores the clinical presentation of gastroparesis, the pharmacology of Ozempic, mechanistic pathways that may connect the drug to gastroparesis, and risk considerations relevant to affected patients, including settlement-related factors.

Clinical Evidence Linking Ozempic to Gastroparesis

Gastroparesis presents with symptoms such as nausea, vomiting, early satiety, postprandial fullness, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy showing delayed emptying. The condition can lead to malnutrition, dehydration, and impaired quality of life. In the context of Ozempic use, gastrointestinal adverse reactions are well-documented. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (placebo 1.9%, Ozempic 0.5 mg 3.5%, Ozempic 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While these data do not explicitly list gastroparesis, the spectrum of upper gastrointestinal symptoms overlaps significantly with gastroparesis presentation.

Mechanistic Pathways and Risk Considerations

Mechanistically, GLP-1 receptor agonists like Ozempic slow gastric emptying as part of their pharmacodynamic action. This effect is mediated through vagal nerve activation and inhibition of antral contractions, leading to delayed transit of gastric contents. In susceptible individuals, this pharmacologic effect may become pathologic, resulting in clinically significant gastroparesis. The dose-dependent increase in gastrointestinal adverse reactions supports a causal relationship, as higher doses of Ozempic (2 mg) were associated with a higher incidence of gastrointestinal adverse reactions (34.0%) compared to 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The timing of symptoms during dose escalation further suggests that the drug's effect on gastric motility is a key factor. Risk considerations for patients who develop gastroparesis after Ozempic use include the adequacy of warnings. The prescribing information for Ozempic includes warnings about serious hypersensitivity reactions such as anaphylaxis and angioedema (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), but does not specifically warn about gastroparesis. The label notes that gastrointestinal adverse reactions are common and that patients may discontinue treatment due to these reactions, but it does not explicitly address the risk of delayed gastric emptying leading to gastroparesis. This gap in specific warnings may be relevant for patients who experience severe or persistent symptoms.

Settlement Criteria and Legal Context

Settlement-related considerations for affected patients hinge on establishing a causal link between Ozempic exposure and the development of gastroparesis. Key factors include the timeline between exposure and documented harm. Patients who develop symptoms during dose escalation or shortly after initiating Ozempic may have a stronger temporal association. The clinical documentation of gastroparesis through gastric emptying studies, along with exclusion of other causes, is critical. Additionally, the severity of harm—such as hospitalization, need for nutritional support, or long-term disability—may influence settlement criteria. Patients should be aware that the current label does not list gastroparesis as a specific adverse reaction, which may affect legal arguments regarding inadequate warnings. In summary, the evidence indicates that Ozempic is associated with a high incidence of gastrointestinal adverse reactions, including symptoms consistent with gastroparesis. The mechanistic slowing of gastric emptying by GLP-1 receptor agonists provides a plausible pathway. Patients who develop gastroparesis after Ozempic use should consider the timing of symptoms, the dose received, and the adequacy of warnings in their risk assessment. Settlement considerations will likely require clear documentation of harm and a temporal link to the drug.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Ozempic and gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying as part of its mechanism. Clinical trials show a high incidence of gastrointestinal adverse reactions, including nausea, vomiting, and dyspepsia, which overlap with gastroparesis symptoms. While the label does not specifically list gastroparesis, the dose-dependent increase in GI reactions and timing during dose escalation suggest a plausible causal link. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166)

What are the settlement criteria for Ozempic gastroparesis lawsuits?

Settlement criteria typically require establishing a causal link between Ozempic exposure and gastroparesis. Key factors include a temporal association (symptoms during dose escalation or shortly after starting), documented diagnosis via gastric emptying scintigraphy, exclusion of other causes, and severity of harm (e.g., hospitalization, nutritional support). The absence of a specific gastroparesis warning on the label may strengthen claims regarding inadequate warnings.

Does the Ozempic label warn about gastroparesis?

No, the current prescribing information for Ozempic does not specifically warn about gastroparesis. It includes warnings about serious hypersensitivity reactions such as anaphylaxis and angioedema (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), and notes that gastrointestinal adverse reactions are common, but does not explicitly address the risk of delayed gastric emptying leading to gastroparesis.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.